Return to Previous Page

NCCN Updates NHL Guidelines


Two recent FDA approvals have prompted the National Comprehensive Cancer Network to update the NCCN Clinical Practice Guidelines in Oncology™ for Non-Hodgkin’s Lymphomas to include ofatumumab (Arzerra™, Glaxo- SmithKline) and romidepsin (Istodax®, Gloucester Pharmaceuticals) as treatment options for selected people with two types of non-Hodgkin’s Lymphomas.

Ofatumumab was added to the NCCN Guidelines as a treatment option for relapsed/refractory disease in people with chronic lymphocytic leukemia. In addition, the updated NCCN Guidelines now include romidepsin as a suggested systemic treatment option for people with mycosis fungoides and Sézary syndrome, two of the most common types of cutaneous T-cell lymphoma.

The most recent version of this and all the NCCN Guidelines are available at

♦ ♦ ♦ ♦ ♦

This article was published in Coping® with Cancer magazine, January/February 2010.